Related Experiment Videos
Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as
Vance G Nielsen1, Brad L Steenwyk, William Q Gurley
1Department of Anesthesiology, The University of Alabama at Birmingham, Birmingham, Alabama 35249-6810, USA. vnielsen@uab.edu
Summary
Direct thrombin inhibitors (DTIs) prolong clot initiation but poorly attenuate clot strength, unlike heparin. This study investigated DTI effects on clot kinetics, revealing potential risks during cardiopulmonary bypass.
Area of Science:
- Cardiovascular Research
- Hematology
- Pharmacology
Background:
- Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy.
- Direct thrombin inhibitors (DTIs) are used for anticoagulation in cardiopulmonary bypass (CPB).
- Thrombosis within the CPB circuit has been reported following DTI administration, necessitating further investigation.
Observation:
- In vitro thrombelastography assessed the impact of heparin and DTIs (argatroban, bivalirudin, lepirudin) on clot kinetics.
- Heparin significantly inhibited clot initiation, propagation, and strength in a dose-dependent manner.
- DTIs generally prolonged clot initiation time but showed limited impact on clot propagation and strength, except for lepirudin at 10 microg/ml.
Findings:
- DTIs significantly prolong the initial phase of clot formation (R time).
- DTIs demonstrate poor attenuation of clot propagation (MTG) and strength (MG) compared to heparin.
- Lepirudin at 10 microg/ml was the only DTI to effectively eliminate coagulation in vitro.
Implications:
- DTIs may not provide adequate protection against thrombosis during CPB in HIT patients.
- Further research is needed to develop DTI regimens that mimic heparin's anticoagulant efficacy.
- Clinical investigations are crucial to optimize anticoagulation strategies for HIT patients undergoing CPB.